Red Blood Cell & Iron Disorders

Red Blood Cell & Iron Disorders

A collection of features and news articles published in ASH Clinical News related to red blood cell and iron disorders.

The Year in FDA Approvals

Here, we review recent therapies approved by the U.S. Food and Drug Administration for the treatment of red blood cell and iron disorders, including...
Sickle cell anemia

Hydroxyurea Treatment Before Puberty Does Not Impair Future Sperm Quality in Boys With SCD

Childhood hydroxyurea (hydroxycarbamide) treatment does not impair future sperm parameters in boys with severe sickle cell disease (SCD), according to research published in Blood....

Questions and Controversies in Iron-Deficiency Anemia

Iron-deficiency is the most common nutritional deficiency in the world. It affects patients in both developed and developing countries and has been commonly recognized...

Inhaled Vaporized Cannabis Yields No Analgesic Benefit in Patients With SCD

Inhalation of vaporized cannabis did not significantly reduce self-reported pain levels or disease-related symptoms in adults with sickle cell disease (SCD) compared with placebo,...
Sickle cell anemia

CRISPR-Based Therapy Receives Rare Pediatric Disease Designation for Sickle Cell Disease

The FDA granted Rare Pediatric Disease (RPD) designation to EDIT-301, an experimental, autologous cell therapy for the treatment of sickle cell disease (SCD). The...

Givosiran Reduces Porphyria Attacks Among Patients With Acute Intermittent Porphyria

Compared with placebo, treatment with the RNA interference therapy givosiran lowered the rate of porphyria attacks in patients with acute intermittent porphyria, the most...

Higher Hydroxyurea Dose Does NOHARM in Sub-Saharan African Children With Sickle Cell Disease

According to results from the NOHARM (Novel use Of Hydroxyurea in an African Region with Malaria) maximum tolerated dose (MTD) trial, dose-escalated hydroxyurea controlled...
On location

Pegcetacoplan Outperforms Eculizumab for Paroxysmal Nocturnal Hemoglobinuria

Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with paroxysmal...

Global Blood Therapeutics Seeks Approval of Voxelotor for Pediatric Sickle Cell Treatment

Next year, Global Blood Therapeutics Inc. (GBT) will seek expanded approval of the use of its treatment for sickle cell disease (SCD), voxelotor, in...

Luspatercept-aamt Approved for Anemia in Adults With MDS

The FDA has approved luspatercept-aamt for the treatment of anemia that requires 2 or more red blood cell transfusions over 8 weeks in adults...
Advertisement

Current Issue

October 2020 Volume 6, Issue 12

This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.

Block title